ARTICLES|ONLINE FIRST Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial The ITAC (INSIGHT 013) Study Group Lancet Published: January 27, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00101-5 Summary Background Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, sp...

ARTICLES|ONLINE FIRST Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial Aurélien Mazeraud, Matthieu Jamme, Rossella Letizia Mancusi, et al Lancet Respir Med Published: November 11, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00440-9 Summary Background Acute respiratory distress syndrome (ARDS) is a major complic...

ARTICLES| VOLUME 399, ISSUE 10323, P437-446, JANUARY 29, 2022 Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study Nicole Wolter, Waasila Jassat, Sibongile Walaza, et al Lancet 2022; 399: 437-446 DOI: https://doi.org/10.1016/S0140-6736(22)00017-4 Summary Background The SARS-CoV-2 omicron variant of concern was identified in South Africa in November, 2021, and was associated with an incr...

ARTICLES|ONLINE FIRST Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study Jean-Pierre Gangneux, Eric Dannaoui, Arnaud Fekkar, et al Lancet Respir Med Published: November 26, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00442-2 Summary Background Patients with severe COVID-19 have emerged as a population at high risk of invasive fungal infections (IFIs). However, to our knowl...

ARTICLES|ONLINE FIRST Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial Zelalem Temesgen, Charles D Burger, Jason Baker, et al Lancet Respir Med Published: December 01, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00494-X Summary Background The pathophysiology of COVID-19 includes immune-mediated hyperinflammation, which could potentially lead to respiratory failure and death. Gra...

ARTICLES|ONLINE FIRST Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis Mary K Dahmer, Guangyu Yang, Min Zhang, et al Lancet Respir Med Published: December 06, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00382-9 Summary Background Previous latent class analysis of adults with acute respiratory distress syndrome (ARDS) identified two phenotypes, distinguished by the degree of inflam...

ORIGINAL ARTICLE Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients Robert L. Gottlieb, Carlos E. Vaca, Roger Paredes, et al N Engl J Med 2022; 386:305-315DOI: 10.1056/NEJMoa2116846 Abstract BACKGROUND Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for...

ARTICLES|ONLINE FIRST Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial Mahir Karakas, Ibrahim Akin, Christoph Burdelski, et al Lancet Respir Med Published: December 08, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00439-2 Summary Background Cardiogenic shock has a high mortality on optimal therapy. Adrenomedullin is released ...

ARTICLES| VOLUME 9, ISSUE 12, P1427-1438, DECEMBER 01, 2021 Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial Jozefien Declercq, Karel F A Van Damme, Elisabeth De Leeuw, et al Lancet Respir Med 2021; 9: 1427-1438 Summary Background Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 and IL-6 ...

ARTICLES| VOLUME 9, ISSUE 12, P1419-1426, DECEMBER 01, 2021 Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet Respir Med 2021; 9: 1419-1426 Summary Background Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients admitte...